[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives] Abstract Text:

Antoine Italiano,Benjamin Besse,David Planchard,Jean-Charles Soria,Antoine Italiano,Benjamin Besse,David Planchard,Jean-Charles Soria,

EGFR tyrosine kinase inhibitors are currently included in the therapeutic armamentarium against advanced NSCLC. However, many questions on the use of anti-EGFR treatment in NSCLC still remain to be answered. Although several biological factors that may help identify those who are likely to respond to EGFR-targeted therapies have been reported, their clinical utility in routine practice remains to be determined. Moreover, the better way to combine EGFR targeted therapies with chemotherapy, new biological agents or loco-regional therapies at earlier stages of the disease is still under investigation. Clearly, the results of ongoing and future trials are required for an appropriate use of this new class of agents in NSCLC patients.

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives] Publishing Authors By Initials

A Italiano,B Besse,D Planchard,JC Soria,A Italiano,B Besse,D Planchard,JC Soria,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives] Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Bulletin du cancer

VOLUME: 94

Page Numbers: F177-88

Journal Abbreviation:

ISSN: 1769-6917

DAY: 29

MONTH: 10

YEAR: 2007

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives] Information

Number of References:

LANGUAGE: fre

NlmUniqueID: 72416

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives] Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]

AFFILIATION: Département de médecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif.

Country: France

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bull Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives Related Publications

• A Saporin-6 cDNA containing a precursor sequence coding for a carboxyl-terminal extension.
• A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells.
• A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels.
• Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins.
• Analysis of the psychometric properties of the Spanish version of the Beck Depression Inventory in Argentina.
• Characterization of a saporin isoform with lower ribosome-inhibiting activity.
• Chemoprevention of lung cancer.
• Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.
• Essential oil composition of the different parts of Eryngium corniculatum Lam. (Apiaceae) from Spain.
• Functional analysis of the genetic variability in the F7 gene promoter.
• Generation of new islets from stem cells.
• Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
• Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers.
• Molecular analysis of multiple genetic variants in Spanish FXII-deficient families.
• Multiplex assay for genetic testing of thrombophilia: a method for routine clinical care.
• Nonlinear immunofluorescent assay for androgenic hormones based on resonant structures.
• Nucleotide sequence of cDNA coding for saporin-6, a type-1 ribosome-inactivating protein from Saponaria officinalis.
• Searching for master regulators of transcription in a human gene expression data set.
• Targeting plant toxins to the urokinase and alpha 2-macroglobulin receptors.
• Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process.
• The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated.
• Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.
• Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.
• [Bacteriological aspects of tuberculosis meningitis]
• [Not Available.]
• [Structural anomaly of the fibrin clot with reduction of lys-plasminogen binding, as a cause of familial thrombosis]
• [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]
• [Treatment of megaesophagus by esophagojejunostomy using jejunal loop in the shape of "Y" according to Roux-Herzen.]